On the public citation graph

Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC – a phase II trial

https://doi.org/10.1038/sj.bjc.6603683
0 signed · 43 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/s11864-002-0041-0openalex-snapshot
Non-small-cell lung cancer progression after first-line chemotherapy
inferredcites →https://doi.org/10.1007/s11912-000-0016-xopenalex-snapshot
Second–line chemotherapy for non—small–cell lung cancer
inferredcites →https://doi.org/10.1016/0169-5002(96)85918-6openalex-snapshot
Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
inferredcites →https://doi.org/10.1016/0197-2456(89)90015-9openalex-snapshot
Optimal two-stage designs for phase II clinical trials
inferredcites →https://doi.org/10.1016/j.lungcan.2003.09.001openalex-snapshot
Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial
inferredcites →https://doi.org/10.1016/s0169-5002(86)80110-6openalex-snapshot
Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer
inferredcites →https://doi.org/10.1016/s0959-8049(00)00072-1openalex-snapshot
A phase II study
inferredcites →https://doi.org/10.1038/sj.onc.1207256openalex-snapshot
Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival
inferredcites →https://doi.org/10.1097/00000421-199110000-00009openalex-snapshot
A Randomized Trial with Mitomycin-C/Ifosfamide Versus Mitomycin-C/Vindesine Versus Cisplatin/Etoposide in Advanced Non-Small-Cell Lung Cancer
inferredcites →https://doi.org/10.1136/bmj.311.7010.899openalex-snapshot
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1048openalex-snapshot
In vivoTherapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor
inferredcites →https://doi.org/10.1159/000227528openalex-snapshot
Vinorelbine and Mitomycin C in Anthracycline-Pretreated Patients with Advanced Breast Cancer
inferredcites →https://doi.org/10.1177/030089169408000106openalex-snapshot
Mitomycin «C» and Vinorelbine as Second Line Chemotherapy for Metastatic Breast Carcinoma
inferredcites →https://doi.org/10.1186/bcr1323openalex-snapshot
Targeted therapy against Bcl-2-related proteins in breast cancer cells
inferredcites →https://doi.org/10.1200/jco.1990.8.5.886openalex-snapshot
Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial.
inferredcites →https://doi.org/10.1200/jco.1993.11.10.1866openalex-snapshot
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
inferredcites →https://doi.org/10.1200/jco.1995.13.3.645openalex-snapshot
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer.
inferredcites →https://doi.org/10.1200/jco.2000.18.10.2095openalex-snapshot
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2000.18.12.2354openalex-snapshot
Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens
inferredcites →https://doi.org/10.1200/jco.2004.08.163openalex-snapshot
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
inferredcites →https://doi.org/10.1378/chest.87.3.368openalex-snapshot
Trial of Vindesine plus Mitomycin in Stage-3 Non-small Cell Lung Cancer
inferredcites →https://doi.org/10.3322/canjclin.48.1.6openalex-snapshot
Cancer statistics, 1998

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.1405290openalex-extracted
The Effect of Health Care Expenditures on Survival in Locally Advanced and Metastatic Non Small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s11095-017-2337-6openalex-snapshot
Paclitaxel and Erlotinib-co-loaded Solid Lipid Core Nanocapsules: Assessment of Physicochemical Characteristics and Cytotoxicity in Non-small Cell Lung Cancer
inferred← citeshttps://doi.org/10.1007/s12254-011-0246-7openalex-snapshot
Mitomycin C in combination with vinorelbine or cisplatin and erythropoietin in pretreated patients with in field relapse after radiation therapy of non-small cell lung cancer: a phase II trial of the AIO
inferred← citeshttps://doi.org/10.1016/j.bcp.2015.07.025openalex-snapshot
Minocycline enhances mitomycin C-induced cytotoxicity through down-regulating ERK1/2-mediated Rad51 expression in human non-small cell lung cancer cells
inferred← citeshttps://doi.org/10.1016/j.bmcl.2015.10.048openalex-snapshot
Synthesis of natural phaeosphaeride A derivatives and an in vitro evaluation of their anti-cancer potential
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2009.01.009openalex-snapshot
Second and third line treatment in non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.ejphar.2023.175949openalex-snapshot
Tetracycline antibiotics: Potential anticancer drugs
inferred← citeshttps://doi.org/10.1016/j.lungcan.2007.09.020openalex-snapshot
Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer
inferred← citeshttps://doi.org/10.1016/j.lungcan.2008.01.011openalex-snapshot
Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective study
inferred← citeshttps://doi.org/10.1016/j.procbio.2021.02.004openalex-snapshot
Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
inferred← citeshttps://doi.org/10.1016/j.soc.2008.04.012openalex-snapshot
Regional Chemotherapy for Carcinoma of the Lung
inferred← citeshttps://doi.org/10.1016/j.taap.2011.07.012openalex-snapshot
Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2–ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells
inferred← citeshttps://doi.org/10.1038/aps.2017.53openalex-snapshot
Ginsenosides synergize with mitomycin C in combating human non-small cell lung cancer by repressing Rad51-mediated DNA repair
inferred← citeshttps://doi.org/10.1093/carcin/bgn130openalex-snapshot
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells
inferred← citeshttps://doi.org/10.1111/j.1742-7843.2011.00806.xopenalex-snapshot
Enhancement of Mitomycin C‐Induced Cytotoxicity by Curcumin Results from Down‐Regulation of MKK1/2‐ERK1/2‐Mediated Thymidine Phosphorylase Expression
inferred← citeshttps://doi.org/10.1124/mol.109.061887openalex-snapshot
Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non–Small-Cell Lung Cancer Cells
inferred← citeshttps://doi.org/10.1186/s11658-024-00578-6openalex-snapshot
Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.18632/oncotarget.13237openalex-snapshot
Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells
inferred← citeshttps://doi.org/10.53846/goediss-856openalex-snapshot
Mitomycin/Cisplatin oder Mitomycin/Vinorelbin und Erythropoetin als Therapie bei vorbehandelten Patienten mit Rezidiv eines NSCLC innerhalb des Bestrahlungsfeldes
inferred← citeshttps://doi.org/10.6084/m9.figshare.25670177openalex-snapshot
Additional file 1 of Targeted inhibition of the PI3K/AKT/mTOR pathway by (+)-anthrabenzoxocinone induces cell cycle arrest, apoptosis, and autophagy in non-small cell lung cancer
inferred← citeshttps://doi.org/10.69601/meandrosmdj.1916484openalex-snapshot
Targeting DNA Methyltransferases with a Pemetrexed–Mitomycin C Combination in Bladder Cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.